Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+246K
-
Total reported value, excl. options
-
$159M
-
Value change
-
+$6.84M
-
Number of buys
-
58
-
Number of sells
-
-17
-
Price
-
$13.53
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q2 2020
82 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 55.7M outstanding shares and own 21.13% of the company stock.
Largest 10 shareholders include Aquilo Capital Management, LLC (1.94M shares), Atlas Venture Associates IX, LLC (1.38M shares), Alphabet Inc. (1.11M shares), BlackRock Inc. (950K shares), NOVO Holdings A/S (931K shares), VANGUARD GROUP INC (735K shares), Rock Springs Capital Management LP (615K shares), Artal Group S.A. (545K shares), BVF INC/IL (487K shares), and RENAISSANCE TECHNOLOGIES LLC (330K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.